[go: up one dir, main page]

SG10201913525QA - Pyrimidine derivative - Google Patents

Pyrimidine derivative

Info

Publication number
SG10201913525QA
SG10201913525QA SG10201913525QA SG10201913525QA SG10201913525QA SG 10201913525Q A SG10201913525Q A SG 10201913525QA SG 10201913525Q A SG10201913525Q A SG 10201913525QA SG 10201913525Q A SG10201913525Q A SG 10201913525QA SG 10201913525Q A SG10201913525Q A SG 10201913525QA
Authority
SG
Singapore
Prior art keywords
pyrimidine derivative
pyrimidine
derivative
Prior art date
Application number
SG10201913525QA
Inventor
Makoto Okada
Youichi Nakano
Takashi Nose
Takahiro Nishimoto
Satoshi Maeda
Original Assignee
Aska Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aska Pharmaceutical Co Ltd filed Critical Aska Pharmaceutical Co Ltd
Publication of SG10201913525QA publication Critical patent/SG10201913525QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • C07D239/36One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/04Drugs for disorders of the urinary system for urolithiasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG10201913525QA 2015-10-29 2016-10-28 Pyrimidine derivative SG10201913525QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015212920 2015-10-29
JP2016078697 2016-04-11

Publications (1)

Publication Number Publication Date
SG10201913525QA true SG10201913525QA (en) 2020-02-27

Family

ID=58630549

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201913525QA SG10201913525QA (en) 2015-10-29 2016-10-28 Pyrimidine derivative
SG11201803357TA SG11201803357TA (en) 2015-10-29 2016-10-28 Pyrimidine derivative

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201803357TA SG11201803357TA (en) 2015-10-29 2016-10-28 Pyrimidine derivative

Country Status (11)

Country Link
US (1) US10710967B2 (en)
EP (1) EP3372589B1 (en)
JP (1) JP6817952B2 (en)
KR (1) KR102649802B1 (en)
CN (1) CN108137513B (en)
AU (1) AU2016346557B2 (en)
CA (1) CA3002632C (en)
DK (1) DK3372589T3 (en)
ES (1) ES2902127T3 (en)
SG (2) SG10201913525QA (en)
WO (1) WO2017073709A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI651310B (en) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 Triterpenoids and their medical use
WO2019044868A1 (en) * 2017-08-30 2019-03-07 あすか製薬株式会社 Pyrimidine derivative
CA3165891A1 (en) * 2019-12-25 2021-07-01 Nippon Shinyaku Co., Ltd. Prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome
JP7277676B2 (en) * 2021-02-02 2023-05-19 あすか製薬株式会社 pyrimidine derivative
CN119497709A (en) 2022-07-06 2025-02-21 Aska 制药株式会社 Pyrimidine derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54113923A (en) 1978-02-25 1979-09-05 Sekisui Jushi Kk Method of assembling partition wall
JPS6310716Y2 (en) 1979-06-19 1988-03-30
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
AR038955A1 (en) * 1996-12-05 2005-02-02 Amgen Inc PIRIMIDINONE AND PIRIDONA SUBSTITUTED COMPOUNDS AND METHODS FOR USE
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
IL130180A0 (en) * 1996-12-05 2000-06-01 Amgen Inc Substituted pyrimidine compounds and their use
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
US6635765B2 (en) * 2000-03-20 2003-10-21 Teva Pharmaceutical Industries, Ltd. Processes for preparing torsemide intermediate
EP1136485A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo Aminophenyl pyrimidone derivatives
CN101747282A (en) * 2008-12-10 2010-06-23 上海特化医药科技有限公司 Phenyl pyrimidone compounds, pharmaceutical compositions and preparation methods and uses thereof
US9216968B2 (en) 2011-08-18 2015-12-22 Nippon Shinyaku Co., Ltd. Heterocyclic derivative and pharmaceutical drug
TWI568722B (en) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 Triazolone compounds as mpges-1 inhibitors
WO2015059618A1 (en) 2013-10-22 2015-04-30 Glenmark Pharmaceuticals S.A. SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS
TWI651310B (en) 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 Triterpenoids and their medical use
US20170057943A1 (en) * 2015-08-17 2017-03-02 Japan Tobacco Inc. Hydroxytriazine compounds and pharmaceutical use thereof

Also Published As

Publication number Publication date
EP3372589A1 (en) 2018-09-12
CN108137513A (en) 2018-06-08
AU2016346557B2 (en) 2020-10-29
JP6817952B2 (en) 2021-01-20
EP3372589A4 (en) 2019-04-24
DK3372589T3 (en) 2021-12-06
CN108137513B (en) 2022-03-01
US20200071280A1 (en) 2020-03-05
ES2902127T3 (en) 2022-03-25
CA3002632C (en) 2023-08-29
WO2017073709A1 (en) 2017-05-04
EP3372589B1 (en) 2021-10-20
KR102649802B1 (en) 2024-03-20
CA3002632A1 (en) 2017-05-04
SG11201803357TA (en) 2018-05-30
JPWO2017073709A1 (en) 2018-08-23
AU2016346557A1 (en) 2018-05-31
US10710967B2 (en) 2020-07-14
KR20180067678A (en) 2018-06-20

Similar Documents

Publication Publication Date Title
ZA201800826B (en) Substituted oxopyridine derivatives
SG11201802832UA (en) Pyrimidine compound
DK3256579T3 (en) Cysteinprotease
DK3298030T3 (en) Anti-cancerfusionspolypeptid
IL253381A0 (en) 9h-pyrrolo-dipyridine derivatives
IL255194A0 (en) Solid forms
DK3380145T3 (en) Injektionsapparat
DK3324768T3 (en) Tørdragt
SG11201803357TA (en) Pyrimidine derivative
IL251005B (en) Pyrido-oxazinone derivatives
AP2016009506A0 (en) Pyrimidine compound
SG11201804610RA (en) Marking-out aid
ZA201802194B (en) Aminoazole derivative
IL255829B (en) Xanthine derivative
GB201509548D0 (en) Give
AU362754S (en) Playsuit
GB201509838D0 (en) Mono-plane
GB201509154D0 (en) Lookma
GB201508638D0 (en) Panel-plane
GB201508572D0 (en) Spirocyclization
GB201507980D0 (en) Bio-cite
GB201507940D0 (en) Chutecase
GB201507783D0 (en) E-calendar
GB201507770D0 (en) Rebarmat
GB201507213D0 (en) Immagine